{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:54:50Z","timestamp":1791975290270,"version":"4.4.0"},"reference-count":42,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"The key construction project on clinical pharmacy","award":["1229"],"award-info":[{"award-number":["1229"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,9,30]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to characterise the prescribing patterns and evaluate the appropriateness of the prescribed proton pump inhibitors (PPIs) in adult patients via a review of electronic medical records in a single-centred hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>All patients admitted to the outpatient department of Jinshan Hospital, Fudan University, Shanghai, between 1 January 2018 and 31 December 2018 were evaluated. Individuals aged 18 years or above and with at least one dispensing for PPIs were identified as PPI users. New PPI users were defined as a subject who did not receive any dispensing for PPIs in the year prior to the index date. Baseline characteristics of PPI users and their therapies were described by treatment indication, economic indicators and co-prescription, overall and separately.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The prescription database was retrieved from the hospital information system of Jinshan Hospital, Fudan University.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 18\u2009435 identified PPI users in 2018, 14 219 patients (aged 18 years or above) who had at least one dispensing PPIs were new users (77%), and among them, men accounted for 47%. The mean treatment duration was 23 days. Omeprazole was the most commonly prescribed drug. PPIs are inappropriately prescribed in 50% (13 589\/25 850) of prescriptions. Prescription appropriateness analysis indicated that the unapproved indications for PPI new users accounted for 47%; among them, the proportion of gastritis diagnosis was 34%. The proportion of PPI new users with co-prescription of glucocorticosteroids (GCs) who have risk factors accounted for 24% and lower than other co-prescription. A majority of PPI users (73%) reported high-dose PPI prescription. The defined daily dose of oral pantoprazole was the highest, and injectable omeprazole had the highest defined daily cost. In contrast, only the drug utilisation index value of oral esomeprazole was less than 1.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results indicate the challenge of PPI use was accompanied by unapproved indications, frequent inappropriate co-prescription with GCs and excessive dosages. Efforts should be paid to promote rational use and ensure the choice of suitable PPI therapy in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-040473","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T15:36:15Z","timestamp":1606404975000},"page":"e040473","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":55,"title":["Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1172-4886","authenticated-orcid":false,"given":"Yujuan","family":"Liu","sequence":"first","affiliation":[{"name":"Clinical Pharmacy Department, Jinshan Hospital Affiliated to Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhu","sequence":"additional","affiliation":[{"name":"Emergency Department, Jinshan Hospital Affiliated to Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxin","family":"Li","sequence":"additional","affiliation":[{"name":"Emergency Department, Jinshan Hospital Affiliated to Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, Jinshan Hospital Affiliated to Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Emergency Department, Jinshan Hospital Affiliated to Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"key":"2025121402504819000_10.11.e040473.1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl15502"},{"key":"2025121402504819000_10.11.e040473.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39406.449456.BE"},{"key":"2025121402504819000_10.11.e040473.3","unstructured":"NHS Digital . Prescription Cost Analysis England 2018, Prescribing & Medicines Team, NHS Digital Responsible Statistician: Ian Bullard. Available: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/prescription-cost-analysis\/2018"},{"key":"2025121402504819000_10.11.e040473.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-014-0638-6","article-title":"Prescribing efficiency of proton pump inhibitors in China: influence and future directions","volume":"15","author":"Zeng","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"2025121402504819000_10.11.e040473.5","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X12437358"},{"key":"2025121402504819000_10.11.e040473.6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s11096-019-00955-8","article-title":"The inappropriate use of proton pump inhibitors during admission and after discharge: a prospective cross-sectional study","volume":"42","author":"Sattayalertyanyong","year":"2020","journal-title":"Int J Clin Pharm"},{"key":"2025121402504819000_10.11.e040473.7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.tcm.2018.10.008","article-title":"Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: are they safe?","volume":"29","author":"Corsonello","year":"2019","journal-title":"Trends Cardiovasc Med"},{"key":"2025121402504819000_10.11.e040473.8","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s12325-017-0532-9","article-title":"A review of the novel application and potential adverse effects of proton pump inhibitors","volume":"34","author":"Yu","year":"2017","journal-title":"Adv Ther"},{"key":"2025121402504819000_10.11.e040473.9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/ajhp\/zxz032","article-title":"Predictors of Clostridioides difficile recurrence across a national cohort of veterans in outpatient, acute, and long-term care settings","volume":"76","author":"Appaneal","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"2025121402504819000_10.11.e040473.10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.bone.2015.08.024","article-title":"The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: a prospective cohort study","volume":"81","author":"van der Hoorn","year":"2015","journal-title":"Bone"},{"key":"2025121402504819000_10.11.e040473.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2017.10.020"},{"key":"2025121402504819000_10.11.e040473.12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40801-019-0157-1","article-title":"Patterns of high-dose and long-term proton pump inhibitor use: a cross-sectional study in six South Australian residential aged care services","volume":"6","author":"Hendrix","year":"2019","journal-title":"Drugs Real World Outcomes"},{"key":"2025121402504819000_10.11.e040473.13","unstructured":"Association CP . Expert consensus on optimal application of PPIs. Chin J Hosp Pharm 2020."},{"key":"2025121402504819000_10.11.e040473.14","first-page":"1045","article-title":"Expert consensus on the rational use of proton pump inhibitors in the elderly in China","volume":"34","year":"2015","journal-title":"Chin J Geriatr"},{"key":"2025121402504819000_10.11.e040473.15","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3642-8"},{"key":"2025121402504819000_10.11.e040473.16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00228-019-02798-8","article-title":"Consumption of medicines used for gastric acid-related disorders in Australia and South Korea: a cross-country comparison","volume":"76","author":"Yu","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2025121402504819000_10.11.e040473.17","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/fampra\/cmz025","article-title":"Prescribing of proton-pump inhibitors: auditing the management and reasons for prescribing in Danish general practice","volume":"36","author":"Jarb\u00f8l","year":"2019","journal-title":"Fam Pract"},{"key":"2025121402504819000_10.11.e040473.18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000488506","article-title":"Prescription pattern of proton pump inhibitors at hospital admission and discharge","volume":"26","author":"Gamelas","year":"2019","journal-title":"GE Port J Gastroenterol"},{"key":"2025121402504819000_10.11.e040473.19","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/jgh.13712","article-title":"East Asian perspective on the interaction between proton pump inhibitors and clopidogrel","volume":"32","author":"Zou","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"2025121402504819000_10.11.e040473.20","doi-asserted-by":"crossref","first-page":"738","DOI":"10.17235\/reed.2019.6155\/2019","article-title":"The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China","volume":"111","author":"Ying","year":"2019","journal-title":"Rev Esp Enferm Dig"},{"key":"2025121402504819000_10.11.e040473.21","unstructured":"World Health Organization . WHO model list of essential medicines 20th edition. Available: http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/ [Accessed 17 Jan 2019]."},{"key":"2025121402504819000_10.11.e040473.22","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/imj.12757","article-title":"Proton pump inhibitors utilisation in older people in New Zealand from 2005 to 2013","volume":"45","author":"Nishtala","year":"2015","journal-title":"Intern Med J"},{"key":"2025121402504819000_10.11.e040473.23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1586\/erp.11.98","article-title":"Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland","volume":"12","author":"Bennie","year":"2012","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2025121402504819000_10.11.e040473.24","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/pds.1969","article-title":"Marked increase in proton pump inhibitors use in Australia","volume":"19","author":"Hollingworth","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121402504819000_10.11.e040473.25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00228-019-02810-1","article-title":"Use of proton pump inhibitors in adults in France: a nationwide drug utilization study","volume":"76","author":"Lassalle","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2025121402504819000_10.11.e040473.26","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.dld.2020.05.005","article-title":"Appropriateness of proton pump inhibitors treatment in clinical practice: prospective evaluation in outpatients and perspective assessment of drug optimisation","volume":"52","author":"Giannini","year":"2020","journal-title":"Dig Liver Dis"},{"key":"2025121402504819000_10.11.e040473.27","first-page":"122","article-title":"Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization","volume":"16","author":"Thomas","year":"2010","journal-title":"J Manag Care Pharm"},{"key":"2025121402504819000_10.11.e040473.28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-015905"},{"key":"2025121402504819000_10.11.e040473.29","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730100-00005"},{"key":"2025121402504819000_10.11.e040473.30","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/jamainternmed.2016.0603","article-title":"Inappropriate prescription of proton pump inhibitors in the setting of steroid use: a teachable moment","volume":"176","author":"Jones","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2025121402504819000_10.11.e040473.31","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.3109\/00365521.2010.497935","article-title":"\u2018A surviving myth\u2019\u2014corticosteroids are still considered ulcerogenic by a majority of physicians","volume":"45","author":"Mart\u00ednek","year":"2010","journal-title":"Scand J Gastroenterol"},{"key":"2025121402504819000_10.11.e040473.32","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/17512433.2018.1531703","article-title":"Proton pump inhibitors: use and misuse in the clinical setting","volume":"11","author":"Savarino","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2025121402504819000_10.11.e040473.33","unstructured":"U.S. Food and Drug Administration . FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Available: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/Postmarket"},{"key":"2025121402504819000_10.11.e040473.34","article-title":"Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: a systematic review and meta-analysis","volume":"23","author":"Pang","year":"2019","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2025121402504819000_10.11.e040473.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01106.x"},{"key":"2025121402504819000_10.11.e040473.36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204231"},{"key":"2025121402504819000_10.11.e040473.37","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017788","article-title":"Proton pump inhibitors and hypomagnesemia: a meta-analysis of observational studies","volume":"98","author":"Srinutta","year":"2019","journal-title":"Medicine"},{"key":"2025121402504819000_10.11.e040473.38","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.525"},{"key":"2025121402504819000_10.11.e040473.39","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-6-201003160-00003"},{"key":"2025121402504819000_10.11.e040473.40","article-title":"Chronic use of proton-pump inhibitors and iron status in renal transplant recipients","volume":"8","author":"Douwes","year":"2019","journal-title":"J Clin Med"},{"key":"2025121402504819000_10.11.e040473.41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamainternmed.2013.2851","article-title":"Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals","volume":"173","author":"Maggio","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2025121402504819000_10.11.e040473.42","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4043"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-040473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T10:50:55Z","timestamp":1765709455000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-040473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,26]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/bmjopen-2020-040473"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-040473","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}